US FDA approves Replimune's skin cancer drug

REPL•2026-08-06

FDA approves Replimune's skin cancer drug

Aug. 6 (Reuters) - The U.S. Food and Drug Administration has approved Replimune's REPL.O drug for a difficult-to-treat form of skin cancer, the company said on Thursday, giving the biotech firm its first marketed product after years of regulatory setbacks.

US FDA approves Replimune's skin cancer drug

FDA approves Replimune's skin cancer drug

Related News

CytoSorbents Q2 adjusted loss narrows on cost controls

Nutex Health Q2 revenue falls on absence of early-stage IDR process

Bright Mountain Media Q2 net loss narrows on cost management

Revelation Biosciences Q2 FY26 net loss widens 35.97% to $3.32 million

Alector publishes corporate deck highlighting Brain Carrier platform and neurodegenerative disease pipeline